Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Frequency Therapeutics, Inc. FREQ NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
42/100
2/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$1.40
+367.3%

Frequency Therapeutics, Inc. (FREQ) is a Biotechnology company in the Healthcare sector, currently trading at $0.30. It has a SharesGrow Score of 42/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Analyst consensus target is FREQ = $1 (+367.3% upside).

Financials: revenue is $6M, +40.7%/yr average growth. Net income is $117M (loss), growing at -13%/yr. Net profit margin is -1834.5% (negative). Gross margin is 0% (-100 pp trend).

Balance sheet: total debt is $43M against $51M equity (Debt-to-Equity (D/E) ratio 0.85, moderate). Current ratio is 6.9 (strong liquidity). Debt-to-assets is 38.3%. Total assets: $114M.

Analyst outlook: 3 / 7 analysts rate FREQ as buy (43%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 75/100 (Pass), Moat 0/100 (Fail), Future 52/100 (Partial), Income 10/100 (Fail).

$1.40
▲ 367.29% Upside
Average Price Target
The 12-month price target for Frequency Therapeutics, Inc. is $1.40.

FREQ SharesGrow Score Overview

59/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 58/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 75/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 0/100
Gross margin is + market cap
FUTURE 52/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — FREQ

✓
VALUE Pass
100/100
FREQ trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $1, implying +233.8% from the current price $0. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
~
GROWTH Partial
58/100
FREQ: +40.7%/yr revenue is, -13%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
75/100
Balance sheet FREQ: Debt-to-Equity (D/E) ratio 0.85 (moderate), Current ratio is 6.9 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
—
MOAT N/A
N/A
No analyst coverage available for this stock.
~
FUTURE Partial
52/100
Analyst outlook: 3 / 7 analysts rate FREQ as buy (43%). Analyst consensus target is $1 (+233.8% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
FREQ: Net profit margin is -1834.5%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range0.183-5.59
Volume309.16K
Avg Volume (30D)135.08K
Market Cap$10.94M
Beta (1Y)0.77
Share Statistics
EPS (TTM)-12.48
Shares Outstanding$9.4M
IPO Date2019-10-03
Employees46
CEODavid L. Lucchino
Financial Highlights & Ratios
Revenue (TTM)$6.39M
EBITDA$-121.86M
Net Income$-117.26M
Operating Income$-121.86M
Total Cash$75.16M
Total Debt$43.49M
Net Debt$21.66M
Total Assets$113.51M
Price / Earnings (P/E)-0
Price / Sales (P/S)1.71
Analyst Forecast
1Y Price Target$1.40
Target High$1.40
Target Low$1.40
Upside+367.3%
Rating ConsensusHold
Analysts Covering7
Buy 43% Hold 57% Sell 0%
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS5009461089

Price Chart

Track all markets on TradingView
FREQ
Frequency Therapeutics, Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
0.18 52WK RANGE 5.59

People Also View

SRRK
SRRK
Scholar Rock Holding Corporation
$49.32
-0.46%
 OLMA
OLMA
Olema Pharmaceuticals, Inc.
$16.49
+1.17%
 GLUE
GLUE
Monte Rosa Therapeutics, Inc.
$18.23
+4.17%
 ABSI
ABSI
Absci Corporation
$3.17
+0.63%
 ARMP
ARMP
Armata Pharmaceuticals, Inc.
$12.06
-6.37%
 LCTX
LCTX
Lineage Cell Therapeutics, Inc.
$1.63
+2.52%
 STTK
STTK
Shattuck Labs, Inc.
$7.17
+5.75%
 ELYM
ELYM
Eliem Therapeutics, Inc.
$5.11
-0.97%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message